OrbiMed-backed Theseus debuts with $100M round in heroic quest for 'pan-variant' kinase inhibitors

Kyle Blankenship

Despite the promise of kinase inhibitors in treating rare tumors, narrow therapeutic targets for most candidates can halt efficacy the moment a patient’s tumor cells …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

OrbiMed-backed Theseus debuts with $100M round in heroic quest for 'pan-variant' kinase inhibitors

Kyle Blankenship

Sign up to read this article for free.

Lilly beats Novo in bellwether head-to-head weight loss study

Lilly drops body mass ranges from FDA label for weight loss drug

GSK terminates Phase 2 trial of HBV therapeutic vaccine

GSK makes another ADC deal, this time with BioNTech's partner DualityBio

Ipsen secures rights to preclinical T cell engager in $610M pact with French biotech

On heels of MariTide data, Danish obesity biotech discloses €80M Series A

Or­biMed-backed The­seus de­buts with $100M round in hero­ic quest for 'pan-vari­ant' ki­nase in­hibitors

Kyle Blankenship

Sign up to read this article for free.

more like this

Lil­ly beats No­vo in bell­wether head-to-head weight loss study

Lil­ly drops body mass ranges from FDA la­bel for weight loss drug

GSK ter­mi­nates Phase 2 tri­al of HBV ther­a­peu­tic vac­cine

GSK makes an­oth­er ADC deal, this time with BioN­Tech's part­ner Du­al­i­ty­Bio

Ipsen se­cures rights to pre­clin­i­cal T cell en­gager in $610M pact with French biotech

On heels of Mar­i­Tide da­ta, Dan­ish obe­si­ty biotech dis­clos­es €80M Se­ries A

OrbiMed-backed Theseus debuts with $100M round in heroic quest for 'pan-variant' kinase inhibitors

Lilly beats Novo in bellwether head-to-head weight loss study

Lilly drops body mass ranges from FDA label for weight loss drug

GSK terminates Phase 2 trial of HBV therapeutic vaccine

GSK makes another ADC deal, this time with BioNTech's partner DualityBio

Ipsen secures rights to preclinical T cell engager in $610M pact with French biotech

On heels of MariTide data, Danish obesity biotech discloses €80M Series A